Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage small molecule precision medicine company focused on therapies for cancer and genetic diseases, plans to report its second quarter 2026 financial results and corporate highlights after U.S. market close on Thursday, August 6, 2026.
The announcement outlines the timing of the upcoming financial disclosure and related corporate update, allowing investors and analysts to prepare for Relay Therapeutics’ next scheduled earnings communication.
Details
News Market Reaction – RLAY
On Jul 31, the first trading day after this news, RLAY closed 3.19% below the previous close. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner recorded 12 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 31 session.
Key Figures
- Reporting period
- Second quarter 2026
- Financial results and corporate highlights
- Reporting date
- August 6, 2026
- After U.S. financial markets close
Previous Earnings date Reports
-
Scheduled first-quarter results and corporate highlights for May 5
-
Scheduled fourth-quarter and full-year results for February 26
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
small molecule technical
precision medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Mitch Maisel
mmaisel@relaytx.com
Media:
Katie Engleman
1AB
919-333-7722
katie@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.